



Market Announcement

11 October 2023

Arovella Therapeutics Limited (ASX: ALA) – Suspension from Quotation

Description

The securities of Arovella Therapeutics Limited ('ALA') will be suspended from quotation immediately under Listing Rule 17.2, at the request of ALA, pending the release of an announcement in relation to a proposed in-license agreement.

Issued by

Scarlette de Lavaine
Adviser, Listings Compliance (Perth)

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



11 October 2023

Mr Dale Allen
Manager, Listings Compliance
ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

BY EMAIL: tradinghaltspert@asx.com.au

Dear Dale

Arovella Therapeutics Limited (ASX: ALA) – Request for voluntary suspension

Pursuant to ASX Listing Rule 17.2, Arovella Therapeutics Limited ACN 090 987 250 (the Company) requests voluntary suspension of its securities effective immediately pending an announcement regarding a proposed in-license agreement expected to be released on Wednesday 11 October 2023.

The Company is not aware of any reason why this request for voluntary suspension should not be granted.

Please contact me if you require any further information.

Yours sincerely

Phillip Hains
Company Secretary